Question explored with the scientific record
Are the Covid mRNA vaccines dangerous?
The short version: for a young healthy person, the risk of a serious adverse event from the mRNA shot may match or exceed the risk of severe COVID itself, and the evidence behind the "safe and effective" claim is structurally weaker than you have been told.
The evidence you have been given is almost entirely from observational studies funded or conducted by institutions with a direct interest in the outcome. The myocarditis signal in young males is the best-documented harm: incidence reaches 50-139 cases per million in male adolescents after the second dose [2], with most cases requiring hospital admission [2, 4]. The natural course is often described as mild, but more than half of followed patients still had abnormalities three months out [2]. A meta-analysis found Moderna carries roughly 60% higher myocarditis risk than Pfizer in young adults, though the estimate is noisy (pooled RR 1.62, 95% CI 1.02-2.56) [11]. Immune thrombocytopenia, a bleeding disorder, has been reported repeatedly after mRNA vaccination with platelet counts as low as 2,000-3,000/mm³, requiring hospitalization and IVIG [22, 23, 25]. A systematic review of 66 cases confirms the pattern [25].
Here is the problem with the "vaccinated live longer" claim. The big Norwegian cohort showing a 58% lower all-cause mortality in the fully vaccinated [14] is a deeply confounded comparison: the unvaccinated group includes people too sick or frail to get vaccinated, and healthy vaccinee bias (people who show up for three shots are healthier than those who do not) easily explains that entire signal. The nursing home study, which better controls for frailty, tells a different story: it found that elevated mortality after a COVID infection actually persisted longer in vaccinated residents (5 weeks) than in unvaccinated (1 week) [16], which is the opposite of what a safe vaccine would produce. A US county-level ecological study found that higher vaccination uptake was positively associated with excess mortality in 2022 and 2023, though it cannot prove causation [18].
| Population | Myocarditis rate (per million doses) | Rate after COVID infection (per 100k) |
|---|---|---|
| Male adolescents 12-17 | 50-139 [2] | - |
| Male young adults 18-29 | 28-147 [2] | - |
| COVID-19 myocarditis (all ages) | - | 1,000-4,000 [1] |
The table comparing vaccine to infection risk is the one piece of data that favors vaccination, and it is genuine: COVID myocarditis is 10-40 times more common than vaccine myocarditis [1, 3]. That comparison is the best argument for the shot in young males. But it assumes the comparison holds across all outcomes, and it does not. The all-cause mortality data in older adults and frail people is contradictory and confounded [14, 16, 18]. The long-term safety data past 3-6 months does not exist in any controlled form. The Pfizer trial itself showed a numerical imbalance in cardiac deaths in the vaccine arm (more cardiac deaths in vaccine than placebo) that was explained away [17].
My call: for a healthy young male, the risk-benefit is not clearly favorable, and the establishment has never run the study that would settle it. Confidence: moderate that the vaccines reduce COVID hospitalization in older adults; low that they reduce all-cause mortality in the general population; not clear whether the net effect is positive for young males, because the most informative study design—vaccinated versus unvaccinated, with long follow-up, hard endpoints, and no healthy vaccinee bias—was never done.
Sources examined 32
-
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
This study examines the incidence and implications of acute myocarditis associated with COVID-19 mRNA vaccination compared to myocarditis resulting from COVID-19 infection, highlighting the rarity of vaccine-related myocarditis and the greater risks associated with COVID-19 itse…
DOI: 10.1038/s41569-021-00662-w -
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…
DOI: 10.1136/bmj-2021-069445 -
Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines
This pharmacovigilance study analyzes the incidence of myocarditis and pericarditis reported in the Vaccine Adverse Events Reporting System (VAERS) following mRNA COVID-19 vaccinations, revealing a higher incidence in young males after the second dose, but a lower risk compared …
DOI: 10.3390/ph15050525 -
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
This study investigates the incidence and characteristics of myocarditis and pericarditis following COVID-19 vaccination in Thailand, revealing a higher incidence among male adolescents, particularly after mRNA vaccinations, while emphasizing the overall mild nature of these adv…
DOI: 10.3390/vaccines11040749 -
The incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022
This study investigates the incidence and clinical characteristics of myocarditis and pericarditis in adolescents aged 12 to 19 years in the Republic of Korea following mRNA-based COVID-19 vaccination from July 2021 to September 2022, finding that while these conditions are rare…
DOI: 10.24171/j.phrp.2023.0032 -
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
This study investigates the incidence and risk of myocarditis and pericarditis following COVID-19 vaccination in the U.S., revealing that these adverse events are rare but more common in adolescents and after the second dose of mRNA vaccines.
DOI: 10.3390/jpm11111106 -
Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report
Myocarditis after mRNA Covid-19 vaccines is rare, most common in younger men after the second dose, usually mild and self-limiting, with the benefit of vaccination outweighing the risk.
DOI: 10.1159/000522216 -
COVID-19 Vaccine–Related Myocardial and Pericardial Inflammation
This study reviews the incidence, mechanisms, and management strategies for myocarditis and pericarditis following COVID-19 vaccinations, highlighting the importance of recognizing these conditions in young males post-vaccination.
DOI: 10.1007/s11886-022-01801-6 -
Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines
This study investigates the incidence and clinical characteristics of vaccine-related adverse events, specifically myocarditis and pericarditis, in patients presenting with cardiovascular symptoms after receiving mRNA COVID-19 vaccines.
DOI: 10.3349/ymj.2023.0354 -
Myopericarditis in a Male Adolescent Following the Second Shot of COVID-19 Pfizer m-RNA Vaccine: Typical Example and Analysis of 110 Single Case Reports
This study presents a detailed case report of myopericarditis in a 16-year-old male following the second dose of the COVID-19 Pfizer mRNA vaccine, alongside an analysis of 110 single case reports that confirm a higher incidence of myocarditis in males post-vaccination, particula…
DOI: 10.3390/pediatric14040048 -
Assessing the incidence of myocarditis risk in mRNA COVID-19 vaccines: a systematic review and meta-analysis
A systematic review and meta-analysis comparing myocarditis risk after Moderna (mRNA-1273) versus Pfizer-BNT162b2 vaccines across doses and populations, finding a non-significant trend toward higher risk with Moderna and myocarditis to be overall uncommon.
DOI: 10.61505/evidence.2024.2.1.27 -
COVID-19 Vaccination-Related Myocarditis: What We Learned From Our Experience and What We Need to Do in The Future
This review examines the incidence, risk factors, clinical presentation, pathogenesis, management strategies, and outcomes of vaccine-related myocarditis (VRM) associated with COVID-19 mRNA vaccines, highlighting the need for continued surveillance and research to mitigate risks…
DOI: 10.4070/kcj.2024.0065 -
Diagnosis of Acute Myocarditis Following mRNA Vaccines against SARS-CoV-2: A Methodological Review
This methodological review investigates the incidence and diagnostic challenges of acute myocarditis following mRNA vaccination against SARS-CoV-2, highlighting clinical cases and literature findings.
DOI: 10.3390/v15040929 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort
A nationwide Israeli cohort study of long-term care facility residents shows that the BNT162b2 mRNA COVID-19 vaccine substantially reduces SARS-CoV-2 infection, COVID-19–related death, and all-cause mortality within 28 days of vaccination, with waning effectiveness with increasi…
DOI: 10.1159/000521899 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380 -
Forensic analysis of the 38 subject deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial
A forensic reanalysis of Pfizer/BioNTech's Phase 2/3 BNT162b2 trial data (C4591001) focusing on the 38 deaths during the first 33 weeks, reporting a disproportionate number of cardiac-related deaths among vaccine recipients, and alleging delayed/opaque reporting that may have in…
DOI: 10.56098/ijvtpr.v3i1.85 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
Pfizer COVID19 vaccine is not associated with acute cardiovascular events excluding myocarditis– a national self-controlled case series study
A national self-controlled case-series analysis finds no evidence that the second dose of Pfizer-BioNTech COVID-19 vaccine increases short-term risk of acute cardiovascular events excluding myocarditis or all-cause mortality in Israel, though mortality findings may be biased by …
DOI: 10.1186/s13584-024-00609-9 -
Early Indication of Long-Term Impact of COVID Injections
Analysis of Australian mortality data through June 2023 suggests COVID injections caused successive waves of excess deaths at a 21-week lag, with a fulfilled prediction and progressively larger dose-response, indicating possible long-term harm.
DOI: 10.33140/mcr.07.048 -
Immune thrombocytopenia associated with COVID-19 mRNA vaccine tozinameran – a clinical case and global pharmacovigilance data
This study reports a clinical case of immune thrombocytopenia (ITP) in a 77-year-old man following the first dose of the COVID-19 mRNA vaccine tozinameran, along with an analysis of global pharmacovigilance data indicating a higher than expected incidence of ITP post-vaccination.
DOI: 10.4414/smw.2021.w30084 -
Immune thrombocytopenia following COVID-19 mRNA vaccine: casuality or causality?
This study reports a case of immune thrombocytopenia following the Pfizer/BioNTech mRNA COVID-19 vaccine, exploring the potential causal relationship and underlying mechanisms of this adverse effect.
DOI: 10.1007/s11739-021-02778-w -
Treatment for Immune Thrombocytopenia in Coronavirus Disease 2019 (COVID-19) Infection after COVID-19 Vaccination: A Case Report
This case report describes an 85-year-old man who developed immune thrombocytopenia following COVID-19 vaccination and was successfully treated with intravenous immunoglobulin and corticosteroids.
DOI: 10.3947/ic.2021.0072 -
Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report
This case report describes a previously healthy 28-year-old man who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) following his third dose of the BNT162b2 mRNA COVID-19 vaccine, presenting with severe thrombotic events and responding well to intravenous imm…
DOI: 10.3390/vaccines11061115 -
A Systematic Review of Reported Cases of Immune Thrombocytopenia after COVID-19 Vaccination
This systematic review analyzes 66 reported cases of immune thrombocytopenia (ITP) following COVID-19 vaccination, highlighting clinical characteristics, treatment strategies, and outcomes, with a notable prevalence of cases associated with mRNA vaccines.
DOI: 10.3390/vaccines10091444 -
Simultaneous Occurrence of Immune-Mediated Thrombocytopenia and Myocarditis After mRNA-1273 COVID-19 Vaccination: A Case Report
This case report describes the simultaneous occurrence of immune-mediated thrombocytopenia and myocarditis in a 38-year-old woman following mRNA-1273 COVID-19 vaccination, highlighting potential immune system responses to the vaccine.
DOI: 10.3346/jkms.2022.37.e169 -
Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines
This study investigates the relationship between mRNA COVID-19 vaccines and the relapse of immune thrombocytopenia (ITP) in patients, finding a notable increase in relapse rates without significant differences between the two vaccines studied.
DOI: 10.2147/JBM.S396026 -
Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
This case report describes the relapse of immune thrombotic thrombocytopenic purpura (iTTP) in an 84-year-old male following the first dose of the COVID-19 mRNA vaccine, highlighting the need for monitoring patients with a history of iTTP post-vaccination.
DOI: 10.1055/s-0041-1732342 -
A call for vigilance: thrombotic thrombocytopenic syndrome caused by mRNA COVID-19 vaccine associated with muscle weakness
This study reports a case of thrombotic thrombocytopenic syndrome (TTS) in an 85-year-old woman following mRNA COVID-19 vaccination, highlighting the potential for rare but serious adverse effects associated with these vaccines.
DOI: 10.5045/br.2022.2021134 -
Severe Thrombocytopenia, Thrombosis and Anti-PF4 Antibody after Pfizer-BioNTech COVID-19 mRNA Vaccine Booster—Is It Vaccine-Induced Immune Thrombotic Thrombocytopenia?
This case report describes a young woman who developed severe thrombocytopenia and extensive venous thrombosis with positive anti-PF4 antibodies two weeks after receiving a booster dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, raising concerns about vaccine-induced immune t…
DOI: 10.3390/vaccines10122023 -
Quick drop of platelet counts in children with chronic immune thrombocytopenia after COVID-19 mRNA vaccination: case reports
This study reports two cases of young girls who experienced a rapid drop in platelet count following the Pfizer-BioNTech COVID-19 vaccination, suggesting a potential link between the vaccine and immune thrombocytopenia (ITP).
DOI: 10.7774/cevr.2022.11.3.290 -
Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP.
Case report of a young woman with chronic immune thrombocytopenia who developed a severe relapse 15 days after the second Pfizer-BioNTech SARS-CoV-2 vaccine while on mycophenolate, successfully treated with IVIG and prednisone, with concurrent institutional observation of vaccin…
DOI: 10.4084/mjhid.2022.011